CytomX Therapeutics CTMX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's deferred revenue?
- CytomX Therapeutics (CTMX) reported deferred revenue of $17.88M in Q1 2026.
- How has CytomX Therapeutics's deferred revenue changed year-over-year?
- CytomX Therapeutics's deferred revenue decreased by 46.2% year-over-year, from $33.23M to $17.88M.
- What is the long-term trend for CytomX Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), CytomX Therapeutics's deferred revenue has grown at a -8.6% compound annual growth rate (CAGR), from $42.06M to $26.88M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.